.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Novartis
Fuji
Chinese Patent Office
QuintilesIMS
Express Scripts
Harvard Business School
UBS
Federal Trade Commission
Medtronic

Generated: June 27, 2017

DrugPatentWatch Database Preview

Claims for Patent: 4,873,259

« Back to Dashboard

Claims for Patent: 4,873,259

Title: Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
Abstract:Compounds of the formula: ##STR1## wherein R.sub.1 is (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl, (3) C.sub.2 to C.sub.4 alkenyl, or (4) NR.sub.2 R.sub.3, wherein R.sub.2 and R.sub.3 are independently selected from (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl and (3) hydroxyl, but R.sub.2 and R.sub.3 are not simultaneously hydroxyl; wherein X is oxygen, sulfur, SO.sub.2, or NR.sub.4, wherein R.sub.4 is (1) hydrogen, (2) C.sub.1 to C.sub.6 alkyl, (3) C.sub.1 to C.sub.6 alkoyl, (4) aroyl, or (5) alkylsulfonyl; A is selected from C.sub.1 to C.sub.6 alkylene and C.sub.2 to C.sub.6 alkenylene; n is 1-5; Y is selected independently at each occurrence from (1) hydrogen, (2) halogen, (3) hydroxy, (4) cyano, (5) halosubstituted alkyl, (6) C.sub.1 to C.sub.12 alkyl, (7) C.sub.2 to C.sub.12 alkenyl, (8) C.sub.1 to C.sub.12 alkoxy, (9) C.sub.3 to C.sub.8 cycloalkyl, (10) C.sub.1 -C.sub.8 thioalkyl, (11) aryl, (12) aryloxy, (13) aroyl, (14) C.sub.1 to C.sub.12 arylalkyl, (15) C.sub.2 to C.sub.12 arylalkenyl, (16) C.sub.1 to C.sub.12 arylalkoxy, (17) C.sub.1 to C.sub.12 arylthioalkoxy, and substituted derivatives of (18) aryl, (19) aryloxy, (20) aroyl, (21) C.sub.1 to C.sub.12 arylalkyl, (22) C.sub.2 to C.sub.12 arylalkenyl, (23) C.sub.1 to C.sub.12 arylalkoxy, or (24) C.sub.1 to C.sub.12 arylthioalkoxy, wherein substituents are selected from halo, nitro, cyano, C.sub.1 to C.sub.12 alkyl, alkoxy, and halosubstituted alkyl; Z is oxygen or sulfur; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C.sub.1 to C.sub.12 alkoyl, are potent inhibitors of 5- and/or 12-lipoxygenase enzymes. Also disclosed are lipoxygenase inhibiting compositions and a method for inhibiting lipoxygenase activity.
Inventor(s): Summers, Jr.; James B. (Libertyville, IL), Gunn; Bruce P. (Island Lake, IL), Brooks; Dee W. (Libertyville, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:07/138,073
Patent Claims: 1. A compound of the formula: ##STR11## wherein R.sub.1 is (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl, (3) C.sub.2 to C.sub.4 alkenyl, or (4) NR.sub.2 R.sub.3, wherein R.sub.2 and R.sub.3 are independently selected from (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl and (3) hydroxyl, but R.sub.2 and R.sub.3 are not simultaneously hydroxyl;

wherein X is oxygen, sulfur, SO.sub.2, or NR.sub.4, wherein R.sub.4 is (1) hydrogen, (2) C.sub.1 to C.sub.6 alkyl, (3) C.sub.1 to C.sub.6 alkoyl, (4) aroyl, or (5) alkylsulfonyl;

A is selected from C.sub.1 to C.sub.6 alkylene and C.sub.2 to C.sub.6 alkenylene;

n is 1-5;

Y is selected independently at each occurrence from (1) hydrogen, (2) halogen, (3) hydroxy, (4) cyano, (5) halosubstituted alkyl, (6) C.sub.1 to C.sub.12 alkyl, (7) C.sub.2 to C.sub.12 alkenyl, (8) C.sub.1 to C.sub.12 alkoxy, (9) C.sub.3 to C.sub.8 cycloalkyl, (10) C.sub.1 -C.sub.8 thioalkyl, (11) aryl, (12) aryloxy, (13) aroyl, (14) C.sub.1 to C.sub.12 arylalkyl, (15) C.sub.2 to C.sub.12 arylalkenyl, (16) C.sub.1 to C.sub.12 arylalkoxy, (17) C.sub.1 to C.sub.12 arylthioalkoxy, and substituted derivatives of (18) aryl, (19) aryloxy, (20) aroyl, (21) C.sub.1 to C.sub.12 arylalkyl, (22) C.sub.2 to C.sub.12 arylalkenyl, (23) C.sub.1 to C.sub.12 arylalkoxy, or (24) C.sub.1 to C.sub.12 arylthioalkoxy, wherein substituents are selected from halo, nitro, cyano, C.sub.1 to C.sub.12 alkyl, alkoxy, and halosubstituted alkyl;

Z is oxygen or sulfur;

and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C.sub.1 to C.sub.12 alkoyl.

2. A compound of claim 1 having the formula: ##STR12## wherein R.sub.5 is C.sub.1 or C.sub.2 alkyl, or NR.sub.6 R.sub.7 where R.sub.6 and R.sub.7 are independently selected from hydrogen and C.sub.1 or C.sub.2 alkyl; B is CH.sub.2 or CHCH.sub.3 ; W is oxygen or sulfur; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C.sub.1 to C.sub.12 alkoyl.

3. A compound according to claim 1 wherein R.sub.1 is CH.sub.3 .

4. A compound according to claim 1 wherein R.sub.1 is NH.sub.2 .

5. A compound according to claim 1 wherein R.sub.1 is NHCH.sub.3 .

6. A compound according to claim 1 wherein A is --CHCH.sub.3 --.

7. A compound according to claim 1 wherein A is --CH.sub.2 --.

8. A compound according to claim 1 wherein X is sulfur.

9. A compound according to claim 1 wherein X is oxygen.

10. The compound of claim 1 having the formula: ##STR13##

11. The compound of claim 1 having the formula: ##STR14##

12. The compound of claim 1 having the formula: ##STR15##

13. A method for inhibiting 5- and/or 12-lipoxygenase activity in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a compound of claim 1.

14. The method of claim 13 wherein the compound has the formula: ##STR16## wherein R.sub.5 is C.sub.1 or C.sub.2 alkyl, or NR.sub.6 R.sub.7 are independently selected from hydrogen and C.sub.1 or C.sub.2 alkyl; B is CH.sub.2 or CHCH.sub.3 ; W is oxygen or sulfur; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C.sub.1 to C.sub.12 alkoyl.

15. The method of claim 13 wherein R.sub.1 is CH.sub.3.

16. The method of claim 13 wherein R.sub.1 is NH.sub.2.

17. The method of claim 13 wherein R.sub.1 is NHCH.sub.3.

18. The method of claim 13 wherein A is --CHCH.sub.3 --.

19. The method of claim 13 wherein A is --CH.sub.2 --.

20. The method of claim 13 wherein X is sulfur.

21. The method of claim 13 wherein X is oxygen.

22. The method of claim 13 wherein the compound has the formula: ##STR17##

23. The method of claim 13 wherein the compound has the formula: ##STR18##

24. The method of claim 13 wherein the compound has the formula: ##STR19##

25. A pharmaceutical composition for inhibiting 5- and/or 12-lipoxygenase, comprising a pharmaceutical carrier and a therapeutically effective amount of a compound of claim 1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Citi
Queensland Health
Chubb
Julphar
Colorcon
US Department of Justice
Moodys
Healthtrust
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot